CN117562899A - Application of DNJ composition in preparation of medicament for treating osteoporosis - Google Patents
Application of DNJ composition in preparation of medicament for treating osteoporosis Download PDFInfo
- Publication number
- CN117562899A CN117562899A CN202311645649.4A CN202311645649A CN117562899A CN 117562899 A CN117562899 A CN 117562899A CN 202311645649 A CN202311645649 A CN 202311645649A CN 117562899 A CN117562899 A CN 117562899A
- Authority
- CN
- China
- Prior art keywords
- dnj
- composition
- medicament
- osteoporosis
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title description 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 20
- 210000000963 osteoblast Anatomy 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 9
- 240000000249 Morus alba Species 0.000 description 9
- 235000008708 Morus alba Nutrition 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 102100035683 Axin-2 Human genes 0.000 description 5
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000004072 osteoblast differentiation Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000033558 biomineral tissue development Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940124605 anti-osteoporosis drug Drugs 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000010603 microCT Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000009818 osteogenic differentiation Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a DNJ composition in preparing a medicament for treating osteoporosis, and relates to the field of biopharmaceuticals. The active ingredients of the DNJ composition comprise DNJ and DNJ homologs; wherein DNJ homologs include, but are not limited to, alpha-1-C-alkyl-1-deoxynojirimycin, beta-1-C-alkyl-1-deoxynojirimycin. The content of effective components in DNJ composition is 6.9mg/kg-8.8mg/kg. The application of the DNJ composition in preparing the medicament for treating the osteoporosis can be widely used for preparing the medicament for treating the osteoporosis.
Description
Technical Field
The invention relates to the technical field of biological pharmacy, in particular to application of a DNJ composition in preparation of a medicament for treating osteoporosis.
Background
Osteoporosis is the most common skeletal disease affecting the health of residents in China, the early stage of the disease usually has no obvious clinical manifestation, if the disease is not emphasized, the conditions such as pain, spinal deformation, fracture and the like can be caused along with the progress of the disease, and the life quality of patients is seriously affected. Bone homeostasis is maintained by a balance between osteoblast bone formation and osteoclastic bone resorption. The existing anti-osteoporosis drugs on the market mainly comprise basic supplements, namely, drugs for inhibiting bone resorption and drugs for promoting bone formation, but more drugs for inhibiting bone resorption are actually clinically used, so that the basic problem of the senile osteoporosis is difficult to solve, and part of the anti-osteoporosis drugs have partial side effects, so that a natural product capable of promoting bone formation is searched for to develop a new anti-osteoporosis drug.
DNJ full name 1-Deoxynojirimycin, chinese name 1-Deoxynojirimycin, molecular formula C 6 H 13 NO 4 The molecular weight is 163.17, CAS number is 19130-96-2, and the mulberry extract is obtained. DNJ, a natural product, is a potent oral alpha-glucosidase (alpha-glucosidase) inhibitor. The mulberry can grow in tropical to arctic regions, the variety is various, the planting is wide, DNJ can be extracted from different parts of the mulberry, the content of the mulberry is high in the mulberry leaves and the mulberries, and the mulberry branches are the next step. The mulberry species contains various bioactive substances and is widely studied, and the natural product DNJ extracted from the mulberry is known to inhibit postprandial blood sugar, prevent diabetes mellitus and have the effects of reducing blood sugar, losing weight and resisting viruses. There are four main routes to produce DNJ: firstly, extracting from plants such as mulberry and the like; (II) extracting from silkworms; (III) chemical synthesis adopting different synthesis strategies; (IV) its adjuvant therapeutic effects on diabetes have been studied extensively before by fermentation with various Bacillus or Streptomyces, which show that DNJ plays a role in bone formation and bone content in wild-type micePromoting effect, and can be used for preparing medicine for treating osteoporosis.
Disclosure of Invention
The invention aims to provide an application of DNJ composition in preparing a medicament for treating osteoporosis, which can be widely used for preparing the medicament for treating osteoporosis.
To achieve the above object, the present invention provides an application of a DNJ composition in preparing a medicament for treating osteoporosis.
Further, the active ingredients of the DNJ composition comprise DNJ and DNJ homologs; wherein DNJ homologs include, but are not limited to, alpha-1-C-alkyl-1-deoxynojirimycin, beta-1-C-alkyl-1-deoxynojirimycin.
Further, the content of the active ingredient in the DNJ composition is 6.9mg/kg-8.8mg/kg.
Further, the medicament comprises powder, granule, tablet, capsule, pill, solution, suspension or injection.
Further, the structure of DNJ is shown as
Further, the DNJ composition may further comprise auxiliary ingredients such as carriers, excipients, flavoring agents, etc., which do not affect the effect of the active ingredient.
Further, the DNJ composition increases osteoblast differentiation, repairing damage to osteoblasts from oxidative stress.
The DNJ composition has the advantages and positive effects that:
1. the DNJ composition has the functions of increasing osteoblast differentiation and preventing osteoporosis of a high-fat mouse, and can be used for preparing medicines for treating osteoporosis.
2. The DNJ composition provided by the invention can repair the damage of oxidative stress to osteoblasts, increase the osteogenic differentiation of the cells, and can be used for preparing medicines for treating osteoporosis.
The technical scheme of the invention is further described in detail through the drawings and the embodiments.
Drawings
FIG. 1 shows changes in cancellous bone of an OVX model mouse after DNJ treatment in the present invention, wherein A is a 3D schematic diagram of cancellous bone of the mouse, B is the bone mass/tissue mass of cancellous bone of the mouse, C is the development thickness of cancellous bone structure of the mouse, D is the number of trabeculae of bone of the mouse, and E is the separation degree of cancellous bone structure of the mouse;
FIG. 2 shows the change of cancellous bone of a mouse after DNJ treatment of a high fat diet osteoporosis mouse model according to the present invention, wherein A is a 3D schematic diagram of cancellous bone of the mouse, B is the bone mass/tissue mass of cancellous bone of the mouse, C is the development thickness of cancellous bone structure of the mouse, D is the number of trabeculae of the mouse, and E is the separation degree of cancellous bone structure of the mouse;
FIG. 3 is a graph showing the effect of DNJ on mineral nodule staining following primary osteoblast differentiation in accordance with the present invention;
FIG. 4 shows the effect of DNJ on RNA molecular signaling of HIF1α and AXIN2 in primary osteoblasts according to the present invention.
Detailed Description
The technical scheme of the invention is further described below through the attached drawings and the embodiments. Unless defined otherwise, technical or scientific terms used herein should be given the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs. In the examples below, biochemical reagents not specifically described are all conventional in the art and can be formulated according to conventional methods in the art or are commercially available in the laboratory pure grade format.
In the drug screening experiment adopted by the invention, the micro-CT detection of the thighbone after various mice are killed is a classical animal bone mass detection experiment, and the osteoblast mineralization nodule staining experiment is a classical experiment for detecting the osteoblast function, so that the reliability of the screening result can be ensured.
Example 1 effect of DNJ on wild type C57BL6J female mouse bone after OVX surgery.
Experimental animals: c57BL6J mice, females, supplied by si Bei Fu laboratory animal technologies limited. Mice were subjected to OVX surgery at 16 weeks of age, single cage after surgery, free water, i.e. i.p. injection of DNJ and control saline for 6 weeks starting at 17 weeks of age, then sacrificed and femur was taken for micro-CT scan to detect bone mass.
Experimental medicine: DNJ drug was purchased from selectk reagent company under the product number S3839.NaCl was purchased from biosharp reagent company.
Experimental equipment: weighing scale, scissors, forceps and injector.
The experimental steps are as follows:
OVX surgery:
after anesthetizing the mice, the mice were shaved, and no hair was required for about 1 cm of wound. The skin surface of the mice was sterilized with iodophor and then sterilized with 75% alcohol. The abdominal cavity was opened, the ovaries were found, the ovaries were removed after ligating the fallopian tubes (the control group opened the abdominal cavity, and the ovaries were found by the same procedure, but without excision). The peritoneal and skin layers were sutured separately, the wound surface was spiked with antibiotic, and mice were injected with 0.1g/kg body weight of antibiotic and 200 μl of 20% glucose.
Treatment of the abdominal cavity of the animal:
the mice were intraperitoneally injected with DNJ at 80mg/kg body weight daily, and the control group was intraperitoneally injected with physiological saline, and the body weight was measured at 10 morning daily. After 6w of intraperitoneal injection, the femur was sacrificed and collected for scanning analysis of bone mass and thickness.
Statistical analysis:
experimental results are expressed as mean ± SEM, and significance between different treatment groups is analyzed by t-test.
Analysis of results:
as shown in fig. 1, adult wild-type C57BL6J females were subjected to OVX surgery as a model of estrogen deficiency induced osteoporosis, and DNJ (80 mg/kg body weight/day) treated by intraperitoneal injection for 6 weeks showed a significant increase in bone mass in the DNJ-treated groups (animals=6, p < 0.05 per group). The results show that DNJ can significantly increase bone mass/tissue mass and cancellous bone content of the femur of OVX mice.
Example 2 effect of DNJ on bone of wild type C57BL6J male mice fed with high fat.
Experimental animals: c57BL6J mice, male, supplied by s Bei Fu laboratory animal technologies inc. Wild mice are fed with high-fat grains from 4 weeks of age, DNJ and normal saline of a control group are injected intraperitoneally after 14w for 8 weeks, and the mice are sacrificed, and femur is taken for micro-CT scanning to detect bone mass.
Experimental medicine: DNJ drug was purchased from selectk reagent company under the product number S3839.NaCl was purchased from biosharp reagent company. High fat feeds were purchased from research diets, cat No. D12493. The common feed is provided by animal houses of Chinese agricultural university.
The experimental steps are as follows:
constructing a high-fat mouse model:
wild mice are fed with high-fat grains from the age of 4 weeks, the weight of the wild mice is obviously different from that of a control group after feeding for 10 weeks, the model construction is completed, and the wild mice are continuously fed with high-fat feed in the subsequent intraperitoneal injection process.
Treatment of the abdominal cavity of the animal:
the mice were intraperitoneally injected with DNJ at 80mg/kg body weight daily, and the control group was intraperitoneally injected with physiological saline, and the body weight was measured at 10 morning daily. After 8w of intraperitoneal injection, the femur was sacrificed and collected for scanning analysis of bone mass and thickness.
Statistical analysis: experimental results are expressed as mean ± SEM, and significance between different treatment groups is analyzed by t-test.
Analysis of results:
as shown in fig. 2, wild type C57BL6J male mice were fed a high fat diet for 10 weeks from 4 weeks of age, induced osteoporosis models, and DNJ (80 mg/kg body weight/day) treated by intraperitoneal injection for 8 weeks showed a significant increase in bone mass in the DNJ-treated groups (animals=6, p < 0.05 per group). The results indicate that DNJ can significantly increase bone mass/tissue mass and cancellous bone content of the femur of high fat fed mice.
Example 3 effect of DNJ on osteogenic differentiation of primary osteoblasts in mice.
Experimental animals: the C57BL6J fetal mouse just born. Supplied by the laboratory animal technologies company, s Bei Fu.
Experimental drugs: DNJ drug was purchased from selectk reagent company under the product number S3839. Medium was purchased from Corning, and other chemicals were purchased from Sigma reagent.
Experimental instrument: cell culture plates, cell culture dishes, pipettes, scissors, forceps, centrifuges, 50ml centrifuge tubes.
The experimental steps are as follows:
1. primary cell isolation:
primary osteoblasts were isolated from the skull of a freshly born mouse, after shearing the skull into 2mm square fragments, digested with collagenase type I at 37 degrees celsius, the first two digestions were discarded, and the last three digestions were collected and centrifuged to obtain primary cells, which were cultured in a-MEM medium containing 10% fetal bovine serum.
2. Cell differentiation and drug treatment:
after cells had grown to a density of 100%, they were grown with 200mM H 2 O 2 Cells 4d were stimulated and 1. Mu.M DNJ-treated cells were differentiated throughout, and 10. Mu.g/ml of ascorbic acid and 10mM of beta-glycerophosphate were added to the cell differentiation medium in the form of 10% fetal bovine serum in alpha-MEM medium. Alizing and differentiating for 14 days, and staining with alizarin red to mineralize nodule substances in cells. The difference of mineralization degree is judged by observing the color depth after dyeing.
3. Expression of hif1α and AXIN2 molecular signals in cells:
200mM H 2 O 2 and 1 mu MDNJ to stimulate cells for 24 hours, collecting cells by using Trizol, extracting RNA, carrying out reverse transcription, and detecting the expression levels of HIF1α and AXIN2 by using an RT-PCR method.
Analysis of results: FIG. 3 is a graph showing the nodulation staining of mineral after differentiation of primary osteoblasts by DNJ, as can be seen from FIG. 3, H 2 O 2 Stimulation resulted in reduced primary osteoblast differentiation, and DNJ had a repair effect on this, indicating that DNJ had the effect of repairing hydrogen peroxide damage to primary osteoblasts.
FIG. 4 shows the effect of DNJ on the RNA molecular signals of HIF1α and AXIN2 in primary osteoblasts, H as shown in FIG. 4 2 O 2 Stimulation resulted in an increase in the level of hypoxia-inducible factor hif1α and the inhibitor of bone synthesis of AXIN2 RNA in primary osteoblasts, whereas DNJ treatment significantly reversed their changes, indicating that DNJ has the effect of repairing hydrogen peroxide on primary osteoblast injury.
Alizarin Red Staining (ARS) showed 200mM H 2 O 2 Stimulation of cells significantly reduced osteoblast mineralization nodules while osteoblast mineralization nodules were significantly increased with cells treated with 1 μm DNJ (fig. 3); 200mM H 2 O 2 After 24h of primary osteoblast stimulation, cellular RNA was extracted, wherein hif1α (hypoxia inducible factor 1α) was significantly increased, and hif1α was significantly decreased after 1 μm DNJ administration (fig. 4), indicating that DNJ can repair the damage of oxidative stress to osteoblast cells, increasing osteoblast differentiation of cells.
Therefore, the DNJ composition has the effects of increasing the differentiation of osteoblasts and preventing the osteoporosis of a high-fat mouse, can repair the damage of oxidative stress to the osteoblasts, and can increase the osteogenic differentiation of the cells, and can be used for preparing the medicament for treating the osteoporosis.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention and not for limiting it, and although the present invention has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that: the technical scheme of the invention can be modified or replaced by the same, and the modified technical scheme cannot deviate from the spirit and scope of the technical scheme of the invention.
Claims (3)
- An application of a DNJ composition in preparing a medicament for treating osteoporosis, which is characterized in that: the content of the active ingredients in the DNJ composition is 6.9mg/kg-8.8mg/kg.
- 2. The use according to claim 1, characterized in that: the active ingredients of the DNJ composition comprise DNJ and DNJ homologs; wherein the DNJ homolog is alpha-1-C-alkyl-1-deoxynojirimycin or beta-1-C-alkyl-1-deoxynojirimycin.
- 3. The use according to claim 1, characterized in that: the medicine comprises powder, granule, tablet, capsule, pill, solution, suspension or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311645649.4A CN117562899A (en) | 2023-12-04 | 2023-12-04 | Application of DNJ composition in preparation of medicament for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311645649.4A CN117562899A (en) | 2023-12-04 | 2023-12-04 | Application of DNJ composition in preparation of medicament for treating osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117562899A true CN117562899A (en) | 2024-02-20 |
Family
ID=89884343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311645649.4A Pending CN117562899A (en) | 2023-12-04 | 2023-12-04 | Application of DNJ composition in preparation of medicament for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117562899A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180296542A1 (en) * | 2015-09-22 | 2018-10-18 | Saint Louis University | Iminosugars for improving bone mineral density in bone disease |
-
2023
- 2023-12-04 CN CN202311645649.4A patent/CN117562899A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180296542A1 (en) * | 2015-09-22 | 2018-10-18 | Saint Louis University | Iminosugars for improving bone mineral density in bone disease |
Non-Patent Citations (1)
| Title |
|---|
| 李晶晶等: "1-脱氧野尻霉素的结构修饰及其活性的研究进展", 现代药物与临床, vol. 38, no. 4, 30 April 2023 (2023-04-30), pages 2 - 5 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5080284B2 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND / OR TREATMENT OF BONE DISEASE, FUNCTIONAL FOOD, HEALTHY FOOD AND PHARMACEUTICAL PREPARATION CONTAINING THE COMPOSITION, AND Root-periodontium formation promoter | |
| CN114225037B (en) | Composition for preventing or treating osteoporosis and preparation and application thereof | |
| CN113456645A (en) | Application of DMXAA in preparing medicine for preventing and treating osteoporosis | |
| KR20110036040A (en) | Cognitive disorder-ameliorating agent | |
| CN110840882A (en) | Composition for treating osteoporosis | |
| US7311919B2 (en) | Agents for treating osteoporosis and inhibiting osteoclast formation | |
| KR101451754B1 (en) | A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of lycium root bark and dipsacus asper wall | |
| CN113243446B (en) | Chaff protein extract and preparation method and application thereof | |
| KR100737278B1 (en) | Method for treating bone fracture, comprising step of administering calcium l-threonate compound and calcium l-threonate compound for treating bone fracture | |
| CN107158008B (en) | A kind of pharmaceutical composition for treating myocardial infarction | |
| CN106614426B (en) | A kind of angiostrongylus cantonensis in-vitro culture medium and extracorporeal culturing method | |
| CN113897300A (en) | Bifidobacterium animalis capable of improving skin barrier function damage and skin sensitivity | |
| CN117562899A (en) | Application of DNJ composition in preparation of medicament for treating osteoporosis | |
| JP2006515276A (en) | Furan derivative having preventive and therapeutic effects on osteoporosis and pharmaceutical composition containing the same | |
| JP2009114101A (en) | Medicinal composition for prophylaxis or therapy of periodontal disease, oral hygienic agent, and food composition | |
| WO2023137985A1 (en) | Dietary nutrition supplement for regulating skeletal muscle glucose metabolism and mitochondria generation and use thereof | |
| KR101790031B1 (en) | Pharmaceutical composition for preventing or treating women osteoporosis caused by menopause or ovariectomy osteoporosis comprising panax ginseng extracts, paeonia lactiflora extracts, glycyrrhiza uralensis extracts and chitosan | |
| CN114468150A (en) | Application of gentisic acid in promoting growth and rumen development of young ruminants | |
| CN113648306A (en) | Application of bergamottin in preventing or treating osteoporosis and/or bone loss | |
| CN111632059B (en) | New application of swertiamarin | |
| CN117959269A (en) | Application of pp' -DDE and homologs thereof in preparation of medicines for treating osteoporosis | |
| KR20140093330A (en) | A composition for preventing or treating blood vessel disorders, comprising extracts of Acanthopanax | |
| KR101306199B1 (en) | Composition for prevention or treatment of osteoporosis comprising the phospholipase D inhibitor | |
| WO2023177234A1 (en) | Composition for preventing and treating inflammatory edema, comprising extract of aster glehni fr. schm. as active ingredient | |
| KR20230017676A (en) | Composition for preventing or treating osteoporosis comprising Kalopanax Extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |